Bifogade filer
Correction: Nomination Committee appointed for the annual general meeting 2025 in Magle Chemoswed Holding
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
In the previous press release that was made public on 3 December 2024 it was wrongly stated that Hans Henrik Lidgard is chair of the Nomination Committee. Hedda Lidgard is chair of the Nomination Committee. Furthermore, the press release did not include information regarding who the members of the Nomination Committee were appointed by. The text is corrected below.
Malmö, Sweden – Magle Chemoswed Holding (publ) today announced the composition of the Nomination Committee for the Annual General Meeting 2024.
The Nomination Committee shall, according to decided principles for the appointment of the Nomination Committee, consist of the chairman of the Board and representatives for the three largest shareholders.
The main task of the Nomination Committee is to submit proposals the Board, remuneration for Board work, the election and remuneration of auditors. The Nomination Committee shall be composed of members appointed by the three largest shareholders in the company based on ownership of the company as per the end of September 2024.
Accordingly, the following committee members have been appointed:
- Hedda Lidgard, chair, nominated by Hans Henrik Lidgard
- Morten Bergstrand, nominated by PRS1 ApS
- Joel Eklund, nominated by Fosielund Holding AB
- Hans Henrik Lidgard, chairman of the Board
The Nomination Committee’s proposals will be presented in the Notice to the AGM 2025 and on the company web site, www.maglegroup.com. Shareholders desiring to submit comments or proposals to the nomination committee can send them via e-mail to info@maglegroup.com
For enquiries, please contact:
Magle Group
Justin Pierce, CEO
Email: justin.pierce@maglechemoswed.com
Telephone: +46 (0)70 593 58 21
About Magle Group
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group’s medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com, www.maglegroup.com, www.maglepharmacept.com and www.maglebiopolymers.com.